In patients with CRC who do not respond to 5-FU treatment, as well as in 5-FU-treated CRC cells, increased PLD6 expression is likely associated with chemoresistance through the activation of Wnt/β-catenin signaling. The gene discussed is PLD6; the disease is colorectal carcinoma.